Literature DB >> 18810716

Effect of blood glucose levels on prognosis in acute myocardial infarction in patients with and without diabetes, undergoing percutaneous coronary intervention.

Mariusz Gasior1, Damian Pres, Gabriela Stasik-Pres, Piotr Lech, Marek Gierlotka, Michał Hawranek, Krzysztof Wilczek, Bozena Szyguła-Jurkiewicz, Andrzej Lekston, Zbigniew Kalarus, Krzysztof Strojek, Janusz Gumprecht, Lech Poloński.   

Abstract

BACKGROUND: Diabetes mellitus (DM) is a significant factor regarding poor outcome in patients with myocardial infarction. Recently a new prognostic factor is under consideration - a baseline glucose level on admission. We sought to assess the influence of blood glucose levels on admission on prognosis of patients with acute ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI). METHODS AND
RESULTS: Consecutive patients treated with PCI for STEMI were analyzed. Presence or absence of DM was the first grouping criterion. The secondary criterion was the blood glucose level on admission [threshold >or= 7.8 mmol/L (140 mg/dL)]. Hyperglycemic and non-hyperglycemic subgroups were selected within both DM and non-DM groups according to the threshold. One-year mortality of diabetics was 16.0%. There was no significant difference in 1-year mortality between hyperglycemic and non-hyperglycemic patients with DM. One-year mortality in the non-DM group was 5.6%. Patients without DM but with hyperglycemia showed a higher 1-year mortality rate than non-hyperglycemic patients (8.51% vs. 3.68%, p = 0.001). Multivariate analysis revealed that in the non-DM group blood glucose level (per 1 mmol/L) on admission was a factor affecting 1-year mortality [HR = 1.09 (1.01-1.17)].
CONCLUSIONS: Elevated blood glucose levels in STEMI affect the prognosis of patients without DM; however, it is not an independent death risk factor of patients with DM treated with PCI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18810716

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  11 in total

Review 1.  Hyperglycemia in nondiabetic patients presenting with acute myocardial infarction.

Authors:  Binita Shah; Nicholas S Amoroso; Steven P Sedlis
Journal:  Am J Med Sci       Date:  2012-04       Impact factor: 2.378

2.  First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases.

Authors:  Ewa Dziewięcka; Mateusz Winiarczyk; Matylda Gliniak; Monika Kaciczak; Sylwia Wiśniowska-Śmiałek; Aleksandra Karabinowska; Katarzyna Holcman; Magdalena Kostkiewicz; Marta Hlawaty; Agata Leśniak-Sobelga; Piotr Podolec; Paweł Rubiś
Journal:  Cardiol J       Date:  2020-08-13       Impact factor: 2.737

3.  Acute Phase Hyperglycemia among Patients Hospitalized with Acute Coronary Syndrome: Prevalence and Prognostic Significance.

Authors:  Abbas Ali Mansour; Hameed Laftah Wanoose
Journal:  Oman Med J       Date:  2011-03

4.  Admission glucose and left ventricular systolic function in non-diabetic patients with acute myocardial infarction.

Authors:  Joanna Gierach; Marcin Gierach; Iwona Świątkiewicz; Marek Woźnicki; Grzegorz Grześk; Adam Sukiennik; Marek Koziñski; Jacek Kubica
Journal:  Heart Vessels       Date:  2014-12-25       Impact factor: 2.037

5.  Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study.

Authors:  Eva C Knudsen; Ingebjørg Seljeflot; Abdelnoor Michael; Jan Eritsland; Arild Mangschau; Carl Müller; Harald Arnesen; Geir Ø Andersen
Journal:  Cardiovasc Diabetol       Date:  2010-09-02       Impact factor: 9.951

6.  Increased coronary intervention rate among diabetic patients with poor glycaemic control: a cross-sectional study.

Authors:  Süha Çetin; Mehmet Akif Öztürk; Nadir Barındık; Ersin İmren; Yüksel Peker
Journal:  Bosn J Basic Med Sci       Date:  2014-02       Impact factor: 3.363

7.  Hemoglobin A1c is a better predictor of prognosis following the non-ST elevation acute coronary syndrome than fasting and admission glucose.

Authors:  Marko Kmet; Borut Rajer; Andrej Pernat
Journal:  Wien Klin Wochenschr       Date:  2013-12-03       Impact factor: 1.704

8.  Impact of Admission Glucose on Non-Diabetic Patients with ST-Segment Elevation Myocardial Infarction Treated with Percutaneous Coronary Intervention: A Meta-Analysis.

Authors:  Zhen-Xuan Hao; Yang Liu; Dan-Li Wang; Wen-Jie Han; Lei Wu; Heng-Liang Liu
Journal:  Acta Cardiol Sin       Date:  2016-03       Impact factor: 2.672

9.  Value of oral glucose tolerance test in the acute phase of myocardial infarction.

Authors:  Agata Bronisz; Marek Kozinski; Przemyslaw Magielski; Tomasz Fabiszak; Joanna Gierach; Iwona Swiatkiewicz; Adam Sukiennik; Aldona Kubica; Marek Bronisz; Zofia Grabczewska; Anna Sinkiewicz; Roman Junik; Jacek Kubica
Journal:  Cardiovasc Diabetol       Date:  2011-03-11       Impact factor: 9.951

10.  Impact of newly diagnosed abnormal glucose regulation on long-term prognosis in low risk patients with ST-elevation myocardial infarction: A follow-up study.

Authors:  Eva C Knudsen; Ingebjørg Seljeflot; Michael Abdelnoor; Jan Eritsland; Arild Mangschau; Carl Müller; Harald Arnesen; Geir O Andersen
Journal:  BMC Endocr Disord       Date:  2011-07-29       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.